NDAORALTABLETPriority Review
Approved
Jul 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Clinical Trials (2)
Early Post-marketing Study of Daclatasvir (Daklinza®) + Asunaprevir (Sunvepra®) in the Treatment of Chronic Hepatitis C (CHC) in Adults
Started Nov 2018
0Hepatitis C
Early Post-marketing Study of Daclatasvir (Daklinza) in the Treatment of Chronic Hepatitis C (CHC) in Adults
Started Oct 2015
10 enrolled
Hepatitis C
Loss of Exclusivity
LOE Date
Jun 13, 2031
64 months away
Patent Expiry
Jun 13, 2031
External Resources